Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors

Erasca Inc. (NASDAQ:ERAS) is one of the stocks under $10 to buy now. Earlier on June 2, Erasca announced that the US FDA had cleared its Investigational New Drug/IND application for ERAS-4001. This potential first-in-class and best-in-class pan-KRAS inhibitor is intended for the treatment of patients with KRAS-mutant (KRASm) solid tumors.

This clearance, along with that of ERAS-0015, which is a potential best-in-class pan-RAS molecular glue, occurred in May earlier this year, ahead of the company’s previously anticipated timeline. ERAS-4001 is designed to target multiple KRAS mutations as well as wild-type KRAS while sparing HRAS and NRAS, which could provide a better therapeutic window compared to broader pan-RAS inhibitors.

Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors

A research laboratory full of pharmaceutical bottles and measuring tools.

This differentiated approach aims to overcome treatment resistance to existing pan-RAS and mutant-selective KRAS inhibitors and address unmet needs for the estimated 2.2 million people diagnosed annually worldwide with KRASm tumors. Erasca anticipates disclosing initial Phase 1 monotherapy data for both ERAS-4001 and ERAS-0015 in 2026.

Erasca Inc. is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.